Our Business
We own unique VHH library; PharmaLogical ®Library and unique technology; cDNA display. Also, we have unique platform “The Month” which is the combination of PharmaLogical ®Library and cDNA display. We are using this platform in various fields such as therapeutics, diagnostics, and imaging, and are approaching the world with our next-generation antibody technology, VHH antibodies.
Drug Discovery
High-quality VHH antibodies can be obtained in just one week using in vitro methods without immunizing animals. The system provides a wide range of screening from soluble proteins to membrane proteins using a library of more than 1 trillion VHH candidate molecules. We provide fast and flexible support for drug discovery, combining ethical considerations with high efficiency.
EME and ONO Announce Collaboration Agreement on Creating Novel VHH antibody drug discovery
Drug Discovery Support
We support next-generation drug discovery research with highly accurate screening and analysis, from target selection to drug candidate acquisition, including VHH antibody screening and epitope analysis.
- Humanized VHH Discovery
- Epitope Mapping & Binding Analysis
- CDR Optimization & Affinity Maturation
- Cyclic Peptide Screening and Custom Peptide Library Design
Antibody Characterization
We rigorously analyze the stability and affinity of VHH candidates that exhibit target binding properties. We provide antibody characterization data essential for identifying optimal drug candidates.
- VHH Characterization & Stability Testing
- Tm, Tagg & Aggregation Analysis
Antibody Engineering
We provide comprehensive support for the design, construction, and evaluation of bispecific antibodies, enabling the creation of molecules with both high stability and multifunctionality by taking advantage of the characteristics of VHH antibodies. We can expand the possibilities of next-generation antibody therapeutics by realizing novel binding modes to a variety of targets.
Custom Screening & Engineering
We perform antibody screening against targets that are difficult to obtain by immunological methods, such as membrane proteins and intracellular targets. We can acquire antibodies that can only be obtained by in vitro screening, such as antibodies with cross-species compatibility, antibodies that bind to expressed cells, and antibodies that are acid/alkali resistant.
- Intrabody VHH Screening
- Membrane protein-binding VHH Screening
Diagnostic Drugs
Introducing technologies required at the forefront of the industry. Aiming to improve the accuracy of diagnostic reagents, we also search for the optimal pairing of VHH antibodies. Pairing with existing antibodies is also possible. We promote the development of innovative diagnostic reagents.
- Provide capture and detection pairing search
- Optimized antibody solutions for immunochromatography
- Support for rapid and precise diagnostic drug development
- Modified VHH antibodies (provides purified VHH proteins, Please contact us for capacity)
- Binding affinity data (KD)
Various paid options are available. For more information about our services, please feel free to contact us.
Licensing
Accelerate commercialization of VHH antibodies and new therapies. Build partnerships that leverage cutting-edge technologies through licensing agreements and collaborative research.
VHH Antibody Licensing
Accelerate commercialization of VHH antibodies and new therapies. Build partnerships that leverage cutting-edge technologies through licensing agreements and collaborative research.
Photo-cross linkage puromycin linker for cDNA display synthesizer : For Academia
We offer the cnvK Linker (photo-cross linkage puromycin linker for cDNA display synthesizer) as a research reagent for academic use.
